MRPL13

Across TCGA pan-cancer cohorts, MRPL13 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MRPL13 data layer compared with 27 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MRPL13 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MRPL13 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, LUAD, and LSCC are the cancer types where MRPL13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	II,III,IV	0.298	0.756	.005	11	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	5	view →
LSCC	DFS	Median	III,IV	0.465	0.838	.039	2	view →
PDAC	DFS	Tertile	All	0.458	0.319	.046	2	view →
HNSC	OS	Median	All	0.793	0.904	.027	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MRPL13–CCRCC (DFS)

Open the CCRCC breakdown →